Leighl NB, Hellmann MD, Hui R, et al. KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. J Clin Oncol. 35, 2017 (suppl; abstr 9011).
Onderzoek naar follow-up op afstand
sep 2024
nov 2024 | Longoncologie
nov 2024 | Longoncologie
feb 2024 | Longoncologie
dec 2023 | Uro-oncologie
jun 2021 | Chirurgie, Maag-darm-leveroncologie
feb 2021 | Maag-darm-leveroncologie
sep 2024